|
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma Clinical research trials and Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma. Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma clinical trial. Human subjects often obtain the finest healthcare possible for their Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma  Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
For Condition: recurrent childhood cerebral astrocytoma
Status: Recruiting
Sponsor(s): KS Biomedix ,
Synopsis: RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplasticastrocytoma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy in treating children who have progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma
Details: OBJECTIVES: - Determine the maximum tolerated dose of intratumoral transferrin-CRM107 in pediatric patients with progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma. - Determine the safety of this drug in these patients. - Determine the efficacy of this drug in these patients. - Compare the efficacy of this drug in patients with different histological types of tumor, degrees of transferrin receptor expression, and serum antidiphtheria antibody titer levels. OUTLINE: This is a dose-escalation, open-label, multicenter study. Patients are assigned to 1 of 2 treatment groups by age (5-9 vs 10-18). All patients undergo stereotactic radiosurgery for tumor biopsy and placement of 2 intratumoral silastic infusion catheters pre-loaded with transferrin-CRM107 (Tf-CRM107). - Group 1 (ages 5-9): Patients receive intratumoral Tf-CRM107 over 3-7 days via catheter. Treatment repeats after 6-10 weeks in the absence of unacceptable toxicity. Three cohorts of 3-6 patients receive escalating doses of Tf-CRM107 until the maximum tolerated dose (MTD) is determined. - Group 2 (ages 10-18): Patients receive intratumoral Tf-CRM107 as in group 1. Two cohorts of 3-6 patients receive escalating doses of Tf-CRM107 until the MTD is determined. The MTD in both groups is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for 6 months and then every 3 months for 6 months. PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 5 Years/18 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed glioblastoma multiforme or anaplastic astrocytoma with the following tumor characteristics: - Unifocal - Unilateral and supratentorial - Diameter no greater than 3.5 cm by contrast-enhanced MRI - No more than 1 satellite tumor - Recurrent or progressive disease - Progressive disease defined as at least 25% increase in tumor volume by serial MRI or CT scans and/or at least 15% increase in the largest cross-sectional area of tumor as defined by the area of contrast agent enhancement - Must have received prior conventional treatment comprising both of the following: - Surgery (biopsy or debulking) - Radiation therapy - No evidence of mass effect on CT scan or MRI with more than a 5 mm midline shift and/or nausea, vomiting, reduced level of consciousness, or clinically significant papilledema PATIENT CHARACTERISTICS: Age - 5 to 18 Performance status - Karnofsky 60-100% OR - Lansky Play 50-100% Life expectancy - At least 3 months Hematopoietic - Platelet count at least 100,000/mm^3 - Absolute neutrophil count at least 1,000/mm^3 Hepatic - Bilirubin no greater than 2.0 mg/dL - AST and ALT no greater than 2.5 times the upper limit of normal (ULN) - PT or aPTT no greater than 1.5 times ULN Renal - Not specified Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 2 months after study - No acute viral, bacterial, or fungal infection requiring therapy - Topical treatment for oral candidiasis allowed - No other concurrent medical condition that would preclude anesthesia PRIOR CONCURRENT THERAPY: Biologic therapy - No prior transferrin-CRM107 Chemotherapy - More than 1 month since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - More than 3 months since prior biodegradable polymer wafers - No concurrent chemotherapy Endocrine therapy - Must be on stable dose of steroids for 7 days prior to infusion Radiotherapy - See Disease Characteristics - More than 3 months since prior radiotherapy - More than 3 months since prior stereotactic radiosurgery - More than 6 weeks since prior craniospinal irradiation - No prior brachytherapy - No concurrent radiotherapy Surgery - See Disease Characteristics - More than 1 month since prior surgery including tumor surgery or debulking - No other concurrent surgery Other - More than 30 days since prior investigational agents - No other concurrent investigational therapy - No other concurrent anti-cancer drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PatrickRossi, Study Chair, KS Biomedix
Children's Hospital of Orange County *Recruiting*
Orange, California, 92868-3874
United States
Recruiting William Louden 714-289-4151
Hollings Cancer Center at Medical University of South Carolina *Recruiting*
Charleston, South Carolina, 29425
United States
Recruiting Jeffrey Campbell 843-792-2424
Additional Information:
Study ID Numbers: CDR0000258574; MUSC-10550,KSB-311P/CI/001
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00052624
Other Recurrent Childhood Cerebral Astrocytoma Studies:
1. O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
2. Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
3. Vinorelbine in Treating Children With Recurrent or Refractory Cancers
4. Imatinib Mesylate With or Without Radiation Therapy in Treating Children With Newly Diagnosed or Recurrent Glioma
5. Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Related Studies:
Other recurrent childhood cerebral astrocytoma Clinical Trials
Other California Clinical Trials
Other Orange Clinical Trials
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
|
|
|
|
|
|
|
|
